Sensei Biotherapeutics Announces Executive Promotions
January 06, 2022 08:00 ET
|
Sensei Biotherapeutics
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award
December 16, 2021 09:01 ET
|
Sensei Biotherapeutics
BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
December 13, 2021 16:01 ET
|
Sensei Biotherapeutics
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
November 19, 2021 16:02 ET
|
Sensei Biotherapeutics
BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 12, 2021 07:02 ET
|
Sensei Biotherapeutics
V-domain Ig-containing suppressor of T-cell activation (VISTA) is a novel immune checkpoint protein that has been recognized as an important potential immunotherapeutic target Preclinical data...
Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
November 09, 2021 08:54 ET
|
Sensei Biotherapeutics
- SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer’s...
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
November 03, 2021 09:01 ET
|
Sensei Biotherapeutics
BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 01, 2021 08:05 ET
|
Sensei Biotherapeutics
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
August 04, 2021 07:45 ET
|
Sensei Biotherapeutics
- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model – - Company...
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
August 02, 2021 08:01 ET
|
Sensei Biotherapeutics
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...